

1 2





9 0


INSTITUTO DE
CIÊNCIAS NUCLEARES
APLICADAS À SAÚDE
UNIVERSIDADE DE
COIMBRA

Antero Abrunhosa
ICNAS | ICNAS PHARMA | CIBIT


ICNAS: From Molecules to Man




"From Molecules to Man"



micro-PET



IBA Kiube VE



ICNAS Pharma portfolio

2010



2022




^{18}F	^{11}C	^{13}N	^{68}Ga	^{64}Cu	^{61}Cu	^{89}Zr
^{18}F -FDG ^{18}F -NaF ^{18}F -FCH ^{18}F -FDOPA ^{18}F -FES ^{18}F -FMISO ^{18}F -FLT ^{18}F -* ^{18}F -*	^{11}C -PiB ^{11}C -Raclopride ^{11}C -Flumazenil ^{11}C -PK11195 ^{11}C -Metionine ^{11}C -Beta-CIT ^{11}C -WAY100635 ^{11}C -UCB-J ^{11}C -AMT ^{11}C -JNJ31020028	^{13}N -Ammonia	$^{68}\text{GaCl}_3$ ^{68}Ga -DOTANOC ^{68}Ga -PSMA-11 ^{68}Ga -FAPi ^{68}Ga -Citrate ^{68}Ga -* ^{68}Ga -*	$^{64}\text{CuCl}_2$ ^{64}Cu -ATSM ^{64}Cu -PTSM ^{64}Cu -DOTANOC ^{64}Cu -* ^{64}Cu -*	$^{61}\text{CuCl}_2$ ^{61}Cu -DOTANOC ^{61}Cu -* ^{61}Cu -* ^{61}Cu -* ^{61}Cu -*	^{89}Zr -Oxalate ^{89}Zr -Pembrolizumab ^{89}Zr -Trastuzumab ^{89}Zr -nb01 ^{89}Zr -nb02

Production

Radiotracer	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Total
FDG [¹⁸ F]	322	309	280	337	429	484	517	460	508	537	4183
NaF [¹⁸ F]			3	20	19	14	14	16	24	25	135
FCH [¹⁸ F]		7	49	75	55	26	33	9	13	3	270
PiB [¹¹ C]	40	37	35	87	131	119	178	191	144	160	1122
Raclopride [¹¹ C]		41	22	27	26	3					119
FLT [¹⁸ F]				3							3
FMISO [¹⁸ F]			3								3
Flumazenil [¹¹ C]		8	8	15		5	13	8			57
PK11195 [¹¹ C]			12	15	52	18	18	19	10	5	149
FDOPA [¹⁸ F]				3	14	20	49	8		14	108
DOTA-NOC [⁶⁸ Ga]		85	154	220	354	351	400	267	276	323	2430
Amónia [¹³ N]				6	32	22	33	61	48	22	224
β-CIT [¹¹ C]				3	45	69	38	40	23	18	236
Methionine [¹¹ C]			12	8	12	10	13	13	8	9	85
ATSM [⁶⁴ Cu]				22	13	8					43
PSMA [⁶⁸ Ga]				3	65	254	342	462	463	614	2203



Clinical Trials



Clinical Trials



ICNAS presente... ecossistema de I&D&I




ICNAS presente: ligação ao SNS

12 190

INSTITUTO DE
CIÊNCIAS NUCLEARES
APLICADAS À SAÚDE
UNIVERSIDADE DE
COIMBRA



ICNAS
PRODUÇÃO
UNIPESSOAL
LDA



Cientes Hospitalares - ICNAS

C.Hospitalar Universitário Algarve, EPE
Centro Hosp.e Univ. Coimbra E.P.E.-CHUC
Centro Hospitalar Cova Beira, E.P.E
Centro Hospitalar de Leiria, E.P.E
Centro Hospitalar do Oeste, E.P.E. - Caldas Rainha
Centro Hospitalar do Porto E.P.E
Centro Hospitalar Entre Douro Vouga, EPE - Stª Maria da Feira
Centro Hospitalar Trás os Montes e Alto Douro, EPE
CHTV, E.P.E-Centro Hosp. Tondela-Viseu
Hosp. Distrital Figueira da Foz, E.P.E
Hosp. Divino Espírito Santo, E.P.E de Ponta Delgada
Hospital de Braga, EPE
Hospital de São João-Porto
Hospital Fernando da Fonseca E.P.E
IPO Coimbra Francisco Gentil, E.P.E
Serviço de Saúde RAM E.P.E - Região Autónoma Madeira
U.L.S. Guarda, EPE - Hospital Sousa Martins
U.L.S. Guarda, EPE - Unidade de Seia
ULS - Castelo Branco Hospital- Amato Lusitano


ICNAS presente: ligação ao SNS



INSTITUTO DE
CIÊNCIAS NUCLEARES
APLICADAS À SAÚDE
UNIVERSIDADE DE
COIMBRA



ICNAS
PRODUÇÃO
UNIPessoal
LDA



Cientes ICNAS Pharma

ICNAS 1

ICNAS 2

IPO Lisboa 1

IPO Lisboa 2

CHUC, Coimbra

Fundação Champalimaud

H. Garcia de Horta, Almada

H. Privado 1, Lisboa

H. Privado 2, Lisboa



H. Privado 3, Lisboa

H. Privado 4, Lisboa


Hospital Privado, Porto

Publications


635 publications selected from Web of Science Core Collection
ICNAS (All Fields) or CIBIT (All Fields)



Publications



ICNAS E+D+A+P



■ ICNAS E ■ ECNAS D ■ ICNAS A ■ ICNAS P

“Teranostics”




Personalized medicine:

The right treatment for the right person at the right time

External Beam Therapy



Radionuclide Therapy




“Teranostics”

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Phase 3 Trial of ^{177}Lu -Dotatate for Midgut Neuroendocrine Tumors

N Engl J Med 2017;376:125-35.




www.impactjournals.com/oncotarget/


Oncotarget, Advance Publications 2017

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [^{177}Lu]Lu-PSMA-617 radioligand therapy


Hojjat Ahmadzadehfard^{1,*}, Stephan Scholaut^{1,*}, Rolf Fimmers², Anna Yordanova¹, Stefan Hirzebruch¹, Carl Schlenkhoff¹, Florian C. Gaertner¹, Zool Hilmi Awang¹, Stefan Hauser³ and Markus Essler¹




“ICNAS 2.0”



“ICNAS 2.0” Level -3




“ICNAS 2.0” Level -2





“ICNAS 2.0”

Level -1



Our vision: to built an European Network

Alpha Nodes



THANK YOU!

